The new facility is a contract manufacturing resource that uses aseptic barrier technology.
Pharmalucence expects to take delivery of the isolated filling line by late Spring 2012.
It is anticipated that the line will be available for commercial product production in early 2013.
Pharmalucence president and CEO Glenn Alto said their investment in Bosch technologies will help them achieve the sterility assurance and regulatory compliance for their products and contract manufacturing clients.
Bosch Pharma Liquid Product Division sales manager Miroslav Horvat said upon completion, Pharmalucence will offer New England’s advanced barrier isolated aseptic fill and finish facility operating in the contract manufacturing market.